Levels of plasma glycan-binding auto-IgG biomarkers improve the accuracy of prostate cancer diagnosis

[1]  F. Cappuzzo,et al.  A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. , 2018, Journal of thoracic disease.

[2]  A. Nasierowska-Guttmejer,et al.  Quality and practical aspects of pathological and molecular diagnostics in metastatic colorectal cancer (mCRC) , 2018, Contemporary oncology.

[3]  J. Brooks,et al.  Multi-lectin Affinity Chromatography and Quantitative Proteomic Analysis Reveal Differential Glycoform Levels between Prostate Cancer and Benign Prostatic Hyperplasia Sera , 2018, Scientific Reports.

[4]  Qingchuan Zheng,et al.  Humanization of fibroblast growth factor 1 single‐chain antibody and validation for its antitumorigenic efficacy in breast cancer and glioma cells , 2018, Journal of cellular and molecular medicine.

[5]  Juan Li,et al.  Co-expression of podoplanin and fibroblast growth factor 1 predicts poor prognosis in patients with lung squamous cell carcinoma , 2017, Molecular medicine reports.

[6]  Ursula Sauer,et al.  Analytical Protein Microarrays: Advancements Towards Clinical Applications , 2017, Sensors.

[7]  M. Nakayama,et al.  Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials , 2016, BMC Urology.

[8]  L. Hsieh‐Wilson,et al.  Glycan Engineering for Cell and Developmental Biology. , 2016, Cell chemical biology.

[9]  A. Vigano,et al.  MAP3K11/GDF15 axis is a critical driver of cancer cachexia , 2015, Journal of cachexia, sarcopenia and muscle.

[10]  J. Clements,et al.  Single nucleotide polymorphisms in clinics: Fantasy or reality for cancer?* , 2015, Critical reviews in clinical laboratory sciences.

[11]  Jie Tang,et al.  Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less , 2015, Iranian journal of public health.

[12]  J. Schlom,et al.  ABO blood type correlates with survival on prostate cancer vaccine therapy , 2015, Oncotarget.

[13]  A. Vigano,et al.  MAP 3 K 11 / GDF 15 axis is a critical driver of cancer cachexia , 2015 .

[14]  T. Sjöblom,et al.  Local and systemic protumorigenic effects of cancer-associated fibroblast-derived GDF15. , 2014, Cancer research.

[15]  V. Vasioukhin,et al.  Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis , 2014, Oncotarget.

[16]  J. Schlom,et al.  Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF , 2013, Clinical Cancer Research.

[17]  Mohan Adhyam,et al.  A Review on the Clinical Utility of PSA in Cancer Prostate , 2012, Indian Journal of Surgical Oncology.

[18]  A. Kozubík,et al.  Growth/differentiation factor-15: prostate cancer suppressor or promoter? , 2012, Prostate Cancer and Prostatic Diseases.

[19]  N. Wentzensen,et al.  A systematic review of humoral immune responses against tumor antigens , 2009, Cancer Immunology, Immunotherapy.

[20]  Lori J Sokoll,et al.  Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. , 2009, Journal of proteome research.

[21]  Chung-Yi Wu,et al.  Glycan microarray of Globo H and related structures for quantitative analysis of breast cancer , 2008, Proceedings of the National Academy of Sciences.

[22]  Amanda M White,et al.  Evaluation of surface chemistries for antibody microarrays. , 2007, Analytical biochemistry.

[23]  H. Johnen,et al.  Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. , 2006, Cancer research.

[24]  H. Cammann,et al.  Three new serum markers for prostate cancer detection within a percent free PSA‐based artificial neural network , 2006, The Prostate.

[25]  G. Hampton,et al.  Measurement of Serum Levels of Macrophage Inhibitory Cytokine 1 Combined with Prostate-Specific Antigen Improves Prostate Cancer Diagnosis , 2006, Clinical Cancer Research.

[26]  Debashis Ghosh,et al.  Autoantibody signatures in prostate cancer. , 2005, The New England journal of medicine.

[27]  D Robert Siemens,et al.  Prostatitis and prostate cancer: implications for prostate cancer screening. , 2004, Urology.

[28]  Minoru Fukuda,et al.  Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. , 2004, Glycobiology.

[29]  R. Nagle,et al.  Fibroblast growth factor‐1 transcriptionally induces membrane type‐1 matrix metalloproteinase expression in prostate carcinoma cell line , 2004, The Prostate.

[30]  T. Stamey,et al.  Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. , 2002, Urology.